Analyst Ratings for Syndax Pharmaceuticals
Portfolio Pulse from Benzinga Insights
In the last quarter, Syndax Pharmaceuticals (NASDAQ:SNDX) received 7 bullish and 4 somewhat bullish ratings from analysts. No indifferent, somewhat bearish, or bearish ratings were observed. The company's average 12-month price target is $36.82, an increase of 4.45% from the previous average of $35.25.
October 17, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Syndax Pharmaceuticals received positive analyst ratings, which could boost investor confidence and potentially drive the stock price up in the short term.
Analyst ratings often influence investor sentiment. The positive ratings for Syndax Pharmaceuticals indicate a bullish outlook, which could lead to increased buying activity and a potential increase in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100